To study the effect of BCP on steatosis induction, results showed that BCP significantly reduced intracellular triglyceride accumulation at concentrations ranging from 500 nM to 10 μM, with the maximum effect at 5 μM (22% reduction).
Int J Mol Sci. 2023 Mar 23;24(7):6060
HaCaT keratinocytes
0.1 and 0.2 μg/mL
30 min pretreatment followed by 12 hours (mRNA) or 24 hours (protein)
To evaluate the inhibitory effect of BCP on IL-4-induced TSLP expression. Results showed that BCP dose-dependently inhibited IL-4-induced TSLP mRNA and protein expression.
Int J Mol Sci. 2022 Nov 28;23(23):14861
Peripheral blood monocytes
0.1 -100 nM
30 minutes
To evaluate the effects of BCP-DHA combination on cytokine production in an MRSA infection model. Results showed significant reduction in GM-CSF, TNFα, IL-1, IL-6, and IL-12 levels and an increase in IL-10 levels in the BCP-DHA treatment groups.
Sci Rep. 2022 Nov 10;12(1):19199
Beas
100 µM
48 hours
Assess the toxicity of β-Caryophyllene on normal lung cells Beas, showing no significant toxicity at 100 μM
Molecules. 2022 Nov 30;27(23):8354
A549
75 µM
48 hours
Evaluate the effect of β-Caryophyllene on A549 cell proliferation, showing significant inhibition at 75 μM
Molecules. 2022 Nov 30;27(23):8354
Bone marrow-derived macrophages (BMDMs)
20 µM
6 hours
Inhibited RSL3-induced macrophage ferroptosis and reduced lipid peroxidation
Int J Mol Sci. 2022 Dec 16;23(24):16055
RAW264.7 macrophages
20 µM
6 hours
Inhibited RSL3-induced macrophage ferroptosis and reduced lipid peroxidation
Int J Mol Sci. 2022 Dec 16;23(24):16055
β-Caryophyllene/β-石竹烯 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
BALB/c mice
DNCB-induced AD-like skin inflammation model
Topical application
0.001, 0.1, and 100 μg/mL
Once daily for 20 days
To evaluate the therapeutic effect of BCP on AD-like skin inflammation. Results showed that BCP significantly alleviated DNCB-induced epidermal hyperplasia and inflammatory cell infiltration, and reduced EGR1 and TSLP expression.
Int J Mol Sci. 2022 Nov 28;23(23):14861
Female BALB/c mice
Urinary tract infection model
Intraperitoneal injection
100 mg/kg
Administered at 6 hours post-infection, evaluated at 24 or 72 hours
To evaluate the antibacterial and analgesic effects of β-caryophyllene in a UTI model. Results showed significant reduction in bacterial burden in urine and bladder tissues, and improvements in behavioral responses and bladder inflammation parameters.
Molecules. 2023 May 17;28(10):4144
Mice
Permanent ischemia model (photothrombosis model)
Intraperitoneal injection
3-30 mg/kg
1 hour before and 24 hours after
To evaluate the effects of β-caryophyllene on infarct size, microglial activation, and motor performance. Results showed that 30 mg/kg of β-caryophyllene significantly reduced infarct size but did not significantly alter microglial number or immunofluorescence.
Int J Mol Sci. 2021 Mar 11;22(6):2866
C57BL/6J mice
DSS-induced ulcerative colitis model
Oral
50 mg/kg
Once daily for 7 days
Inhibited macrophage ferroptosis by activating CB2R and alleviated colonic inflammation
Int J Mol Sci. 2022 Dec 16;23(24):16055
Balb-C mice
Acetic acid-induced abdominal writhing, formalin-induced paw edema, and von Frey mechanical hypernociception models
Subcutaneous injection
BCP (5 mg/kg), BCP + DHA (2.5 mg/kg each)
Single dose 24 hours before the test
To evaluate the anti-inflammatory and antinociceptive effects of BCP and DHA alone or in combination. Results showed significant reduction in acetic acid-induced abdominal writhing, formalin-induced paw edema, and von Frey mechanical hypernociception.
Sci Rep. 2022 Nov 10;12(1):19199
Rats and mice
Nicotine self-administration model
Intraperitoneal injection
3, 10, 25, 50, and 100 mg/kg
Single administration, 30 min prior
Systemic administration of BCP dose-dependently inhibited nicotine self-administration and motivation for nicotine seeking in rats and mice. The reduction in nicotine self-administration by low-dose BCP (25 mg/kg) was blocked by the selective CB2 receptor antagonist AM630 but not by the selective CB1 receptor antagonist AM251, suggesting CB2 receptor mechanism involvement. Genetic deletion of CB2 receptors in mice blocked the reduction in nicotine self-administration only at low doses of BCP (25 mg/kg), but not at high doses (50 mg/kg), suggesting involvement of both CB2 and non-CB2 receptor mechanisms.
搜索
